Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have a number of clinical limitations, the most serious long term limitation being the eventual need for insulin replacement therapy. Since 2007, drugs targeting the glucagon like peptide 1 (GLP-1) receptor have been marketed for the treatment of type 2 diabetes. These drugs have enjoyed a great deal of success even though our underlying understanding of the mechanisms for their pleiotropic effects remain poorly characterised even while major pharmaceutical companies actively pursue small molecule alternatives. Coupling of the GLP-1 receptor to more than one signalling pathway (pleiotropic signalling) can result in ligand dependent signalling bias and for a peptide receptor such as the GLP-1 receptor this can be exaggerated with the use of small molecule agonists. Better consideration of receptor signalling pleiotropy will be necessary future drug development. This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP-1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long-acting exenatide long acting release, albiglutide and dulaglutide.
Original languageEnglish
Pages (from-to)1114 - 1128
Number of pages15
JournalBritish Journal of Pharmacology
Volume171
Issue number5
DOIs
Publication statusPublished - 2014

Cite this

@article{d21a14f4b461468a86b96bd13f1e70a6,
title = "Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation",
abstract = "The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have a number of clinical limitations, the most serious long term limitation being the eventual need for insulin replacement therapy. Since 2007, drugs targeting the glucagon like peptide 1 (GLP-1) receptor have been marketed for the treatment of type 2 diabetes. These drugs have enjoyed a great deal of success even though our underlying understanding of the mechanisms for their pleiotropic effects remain poorly characterised even while major pharmaceutical companies actively pursue small molecule alternatives. Coupling of the GLP-1 receptor to more than one signalling pathway (pleiotropic signalling) can result in ligand dependent signalling bias and for a peptide receptor such as the GLP-1 receptor this can be exaggerated with the use of small molecule agonists. Better consideration of receptor signalling pleiotropy will be necessary future drug development. This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP-1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long-acting exenatide long acting release, albiglutide and dulaglutide.",
author = "Kavita Pabreja and Muzaida Mohd and Koole, {Cassandra Renee} and Wootten, {Denise Laura} and Furness, {Sebastian George Barton}",
year = "2014",
doi = "10.1111/bph.12313",
language = "English",
volume = "171",
pages = "1114 -- 1128",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "5",

}

Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. / Pabreja, Kavita; Mohd, Muzaida; Koole, Cassandra Renee; Wootten, Denise Laura; Furness, Sebastian George Barton.

In: British Journal of Pharmacology, Vol. 171, No. 5, 2014, p. 1114 - 1128.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation

AU - Pabreja, Kavita

AU - Mohd, Muzaida

AU - Koole, Cassandra Renee

AU - Wootten, Denise Laura

AU - Furness, Sebastian George Barton

PY - 2014

Y1 - 2014

N2 - The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have a number of clinical limitations, the most serious long term limitation being the eventual need for insulin replacement therapy. Since 2007, drugs targeting the glucagon like peptide 1 (GLP-1) receptor have been marketed for the treatment of type 2 diabetes. These drugs have enjoyed a great deal of success even though our underlying understanding of the mechanisms for their pleiotropic effects remain poorly characterised even while major pharmaceutical companies actively pursue small molecule alternatives. Coupling of the GLP-1 receptor to more than one signalling pathway (pleiotropic signalling) can result in ligand dependent signalling bias and for a peptide receptor such as the GLP-1 receptor this can be exaggerated with the use of small molecule agonists. Better consideration of receptor signalling pleiotropy will be necessary future drug development. This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP-1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long-acting exenatide long acting release, albiglutide and dulaglutide.

AB - The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have a number of clinical limitations, the most serious long term limitation being the eventual need for insulin replacement therapy. Since 2007, drugs targeting the glucagon like peptide 1 (GLP-1) receptor have been marketed for the treatment of type 2 diabetes. These drugs have enjoyed a great deal of success even though our underlying understanding of the mechanisms for their pleiotropic effects remain poorly characterised even while major pharmaceutical companies actively pursue small molecule alternatives. Coupling of the GLP-1 receptor to more than one signalling pathway (pleiotropic signalling) can result in ligand dependent signalling bias and for a peptide receptor such as the GLP-1 receptor this can be exaggerated with the use of small molecule agonists. Better consideration of receptor signalling pleiotropy will be necessary future drug development. This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP-1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long-acting exenatide long acting release, albiglutide and dulaglutide.

UR - http://onlinelibrary.wiley.com/doi/10.1111/bph.12313/pdf

U2 - 10.1111/bph.12313

DO - 10.1111/bph.12313

M3 - Article

VL - 171

SP - 1114

EP - 1128

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 5

ER -